N-Myc Proto-Oncogene Protein
"N-Myc Proto-Oncogene Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A basic helix-loop-helix leucine zipper (bHLHZ) transcription factor and proto-oncogene protein that functions in cell growth and proliferation. In mammals, it is highly expressed in the brain during embryogenesis and is essential for brain development; it is not expressed in adult tissues. Amplification or overexpression of N-Myc occurs in at least 20% of tumors and is associated with a poor prognosis in cases of NEUROBLASTOMA; ALVEOLAR RHABDOMYOSARCOMA; SMALL CELL LUNG CARCINOMA; and neuroendocrine prostate cancer.
| Descriptor ID |
D000071447
|
| MeSH Number(s) |
D12.776.260.103.500.625 D12.776.260.108.092.625 D12.776.624.664.700.158 D12.776.930.125.500.563 D12.776.930.127.092.625
|
| Concept/Terms |
N-Myc Proto-Oncogene Protein- N-Myc Proto-Oncogene Protein
- N Myc Proto Oncogene Protein
- Proto-Oncogene Protein, N-Myc
- BHLHE37 Protein
- NMYC Protein
- Class E Basic Helix-Loop-Helix Protein 37
- Class E Basic Helix Loop Helix Protein 37
- N-Myc Protein
- N Myc Protein
- MYCN Protein
|
Below are MeSH descriptors whose meaning is more general than "N-Myc Proto-Oncogene Protein".
Below are MeSH descriptors whose meaning is more specific than "N-Myc Proto-Oncogene Protein".
This graph shows the total number of publications written about "N-Myc Proto-Oncogene Protein" by people in this website by year, and whether "N-Myc Proto-Oncogene Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 0 | 2 | 2 |
| 2015 | 0 | 2 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "N-Myc Proto-Oncogene Protein" by people in Profiles.
-
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Lett. 2019 08 10; 457:129-141.
-
The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. Cancer Lett. 2017 08 01; 400:61-68.
-
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett. 2016 Feb 28; 371(2):214-24.
-
Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study. Br J Cancer. 2015 Jun 30; 113(1):57-63.
-
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010 Mar; 12(3):247-56.
-
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo. Neoplasia. 2009 Aug; 11(8):753-62.
-
Importance of Sp1 consensus motifs in the MYCN promoter. Surgery. 2002 Aug; 132(2):232-8.